PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 374896

Connective tissues--possible implications of the temporal changes for the aging process.

A Viidik
View original source ↗Export metadata ↓

Abstract

Two of the "old" mono-cause theories of aging have temporal changes in the connective tissues, especially those in collagen, as main events. The crosslinking of collagen is stable under physiological conditions shortly after the formation of fibrils and the additional physico-chemical stability attained later on probably does not influence the physiological functions of the tissues significantly. The temporal changes in collagen seen as increased thermal stability, decreased solubility and increased mechanical stiffness are discussed in relation to the underlying structural changes. It is concluded that the increased stability of the collagen (mainly type I) in the locomotive system and skin are not "true" aging phenomena. It is possible that the changes in the connective tissues of the lungs and kidneys contribute to the decrease of function with age. The "normal" increase of stiffness of type I collagen may contibute to the increased compliance and residual volume of the aging lung. Our present knowledge of the structure and function of collagens and ground substances in various basement membranes does not permit an evaluation of the role of connective tissues in the age changes in the alveolo--capillary complex, the glomeruli and the exchange between tissues and capillaries in general.

Explore related subjects

Adrenal Cortex HormonesAgingAnimalsChemical PhenomenaChemistryCollagenConnective TissueDiabetes MellitusHot TemperatureHumansKidneyLiverLungPhysical ExertionProtein ConformationProtein DenaturationSolubilityThyroxineJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Viidik. 1979. Connective tissues--possible implications of the temporal changes for the aging process.. https://doi.org/10.1016/0047-6374(79)90104-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗
PubMed2007

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗